A melanoma skin cancer immunotherapy treatment made from genetically-engineered cells of the herpes simplex virus-1 may be effective for patients both in early and advanced stages of the disease. Results of a phase three clinical trial, published in the Journal of Clinical Oncology, of the experimental drug found cancer didn’t progress in 16.3 percent of the…
(more…)
Leave a Reply
You must be logged in to post a comment.